Skip to content

US · SRPT · BIOTECHNOLOGY

Sarepta Therapeutics, Inc. (SRPT) intrinsic value and stock valuation

$13.33as of 2026-11-21 · Mkt cap 1.68B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sarepta Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values SRPT with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SRPT’s statements →

Sarepta Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02142 sarepta.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.2B+32.4% 5y CAGRd
20112025
Net income
-$-713.41M
20112025
Free cash flow
-$-307.45M
20112025
Total equity
$1.14B+8.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.2B$1.9B$1.24B$933M$701.9M
Operating income-$-657.77M$218.1M-$-267.82M-$-536.2M-$-459.71M
Net income-$-713.41M$235.2M-$-535.98M-$-703.49M-$-418.78M
EPSd-$-6.81M$2.18M-$-5.8M-$-8.03M-$-5.15M
Operating cash flow-$-205.48M-$-205.79M-$-500.99M-$-325.35M-$-443.17M
Capital expenditure-$-101.97M-$-146.96M-$-87.34M-$-32.25M-$-38.49M
Free cash flow-$-307.45M-$-352.74M-$-588.34M-$-357.6M-$-481.66M
Total assets$3.35B$3.96B$3.26B$3.13B$3.15B
Total debt$1.04B$1.34B$1.4B$1.62B$1.15B
Net debt$238.5M$240.1M$968.4M$650.6M-$-962.43M
Total equity$1.14B$1.53B$859.3M$385M$928M
Cash and short-term investments$939.7M$1.35B$1.68B$1.99B$2.12B
Income statement
20252024202320222021
Revenue$2.2B$1.9B$1.24B$933M$701.9M
Cost of revenue$881.5M$319.1M$150.3M$140M$97.1M
Gross profit$1.32B$1.58B$1.09B$793M$604.8M
Research and development expenses$1.52B$804.5M$877.4M$877.1M$771.2M
Selling, general and administrative expenses$478.9M$557.9M$481.9M$451.4M$282.7M
Other expenses-$-26.5M$2.4M$1.56M$710K$10.7M
Operating expenses$1.97B$1.36B$1.36B$1.33B$1.06B
Cost and expenses$2.86B$1.68B$1.51B$1.47B$1.16B
Interest income$19.6M$71.8M$86M$27.7M$510K
Interest expense$9.73M$18.4M$22M$53.3M$63.5M
Depreciation and amortization$44.5M$37.7M$44.4M$41.9M$38M
Ebitda-$-647.97M$316.9M-$-453.69M-$-594.85M-$-317.41M
Operating income-$-657.77M$218.1M-$-267.82M-$-536.2M-$-459.71M
Total other income/expenses, net-$-44.45M$42.7M-$-252.27M-$-153.76M$40.8M
Income before tax-$-702.23M$260.8M-$-520.1M-$-689.96M-$-418.95M
Income tax expense$11.2M$25.5M$15.9M$13.5M-$-170K
Net income-$-713.41M$235.2M-$-535.98M-$-703.49M-$-418.78M
Weighted average shares outstanding$104.8M$95.1M$92.4M$87.6M$81.3M
Weighted average diluted shares outstanding$104.8M$107.9M$92.4M$87.6M$81.3M
Balance sheet
20252024202320222021
Cash and short-term investments$939.7M$1.35B$1.68B$1.99B$2.12B
Net receivables$519.6M$649.7M$437M$261.6M$172.8M
Inventory$914.7M$750M$322.9M$204M$186.2M
Total current assets$2.54B$3.07B$2.58B$2.56B$2.6B
Property, plant and equipment, net$470.6M$488.7M$357.1M$245M$236.7M
Goodwill and intangible assets$29M$26.9M$29.6M$7.58M$14.2M
Long-term investments$1.05M$136.9M$6.53M$31.3M$34.9M
Total non-current assets$811.8M$889.7M$685.3M$570.5M$543.9M
Total assets$3.35B$3.96B$3.26B$3.13B$3.15B
Accounts payable$280.8M$214.4M$164.9M$95.9M$76.7M
Short-term debt$11.4M$13.5M$123.3M$15.5M$15.1M
Deferred revenue$443.4M$130.3M$50.4M$89.2M$89.2M
Total current liabilities$1.1B$731.7M$653.7M$619.6M$452.7M
Long-term debt$1.03B$1.33B$1.27B$1.6B$1.14B
Deferred revenue, non-current$83.9M$325M$437M$485M$574.2M
Total non-current liabilities$1.11B$1.7B$1.75B$2.12B$1.77B
Capital lease obligations$210.8M$206M$158.8M$73.1M$56.6M
Total liabilities$2.21B$2.44B$2.41B$2.74B$2.22B
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-4.88B-$-4.21B-$-4.45B-$-3.91B-$-3.21B
Accumulated other comprehensive income (loss)$270K-$-220K$920K-$-1.66M-$-20K
Total equity$1.14B$1.53B$859.3M$385M$928M
Total investments$139.4M$388.7M$1.25B$1.05B$34.9M
Total debt$1.04B$1.34B$1.4B$1.62B$1.15B
Net debt$238.5M$240.1M$968.4M$650.6M-$-962.43M
Cash flow statement
20252024202320222021
Net income-$-713.41M$235.2M-$-535.98M-$-703.49M-$-418.78M
Depreciation and amortization$44.5M$37.7M$44.4M$41.9M$38M
Stock-based compensation$123.4M$184.3M$182.5M$233M$113.9M
Change in working capital$78M-$-716.61M-$-481.09M-$-39.47M-$-98.17M
Accounts receivable$203.8M-$-201.66M-$-185.7M-$-61.64M-$-51.65M
Inventory-$-301.09M-$-395.17M-$-147.71M-$-50.78M-$-83.77M
Accounts payable$104.3M$110.7M-$-50.13M$147.6M$23.3M
Net cash provided by operating activities-$-205.48M-$-205.79M-$-500.99M-$-325.35M-$-443.17M
Investments in property, plant and equipment-$-101.97M-$-136.96M-$-76.11M-$-30.82M-$-38.49M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$69.6M$755.6M-$-165.8M-$-1.05B$495.4M
Common stock issued$36.3M$0.00$0.00$0.00$548.5M
Common stock repurchased-$-25.01M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-168.34M$124.8M$125M$232.5M$561.6M
Net change in cash-$-304.18M$674.6M-$-541.79M-$-1.14B$613.8M
Cash at end of period$814.4M$1.12B$444M$985.8M$2.13B
Operating cash flow-$-205.48M-$-205.79M-$-500.99M-$-325.35M-$-443.17M
Capital expenditure-$-101.97M-$-146.96M-$-87.34M-$-32.25M-$-38.49M
Free cash flow-$-307.45M-$-352.74M-$-588.34M-$-357.6M-$-481.66M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sarepta Therapeutics, Inc.

        Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.

        CEO
        Douglas S. Ingram
        Employees
        835
        Beta
        0.20

        Explore

        Frequently asked questions

        What is the intrinsic value of Sarepta Therapeutics, Inc. (SRPT)?

        Sarepta Therapeutics, Inc. (SRPT) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SRPT undervalued?

        SRPT trades at a price of $13.33 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.